Dragonfly chief: Bristol Myers shouldn’t blame IL-12’s clinical performance for decision to scrap the deal — economics played a key role

Bristol Myers Squibb says the IL-12 drug they were developing out of Dragonfly Therapeutics was scrubbed from the pipeline for a simple reason: It …

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

Drag­on­fly chief: Bris­tol My­ers shouldn’t blame IL-12’s clin­i­cal per­for­mance for de­ci­sion to scrap the deal — eco­nom­ics played a key role